Evolocumab Reduces CV Events in Patients with High-Risk Diabetes: Results from the VESALIUS-CV Trial

Authors
Category Primary study
JournalDIABETES
Year 2026
This article has no abstract
Epistemonikos ID: f63fb0679073e9b98a4fe0cb264a3d7bd904bd1a
First added on: Aug 08, 2026